Press releases
LIDDS Delårsrapport juli – september 2018 LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study LIDDS participates at Redeye Life Science Day LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capabilityCompany Analysis
Lidds
LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.
Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com
Subscribe for news
Press releases
- 2018-11-29 LIDDS Delårsrapport juli – september 2018
- 2018-11-21 LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study
- 2018-11-16 LIDDS participates at Redeye Life Science Day
- 2018-11-15 LIDDS presence at BIO-Europe 2018 to focus on NanoZolid’s broad drug formulation capability
LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com
